Health Action International

23andMe Reports Second Quarter Fiscal 2024 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
FDA, Research, African Americans, 23andMe, PGS, Health, Science, CORE (research service), Society for Immunotherapy of Cancer, Behavior, BRCA1, Consumer, Genetics, EBITDA, Workforce, Health Action International, Premium, Bangladesh Technical Education Board, Inflammation, BRCA2, DNA, Advertising, Pharmacokinetics, Consumer service, SITC, Science (journal), Immunotherapy, Database, Growth, Marketing, Webcast, GSK, GSK plc, Blood, Society, African, Total, Table, Pharmacogenomics, Harvard University, Lijun International Pharmaceutical (Holding) Co. Ltd., SAN, Pharmaceutical industry, Mobile phone, CD200R1, Simvastatin, Therapy

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.
  • Members of Total Health will also receive all the reports and features offered in our existing 23andMe+ Premium Membership.
  • Full year Adjusted EBITDA deficit is reaffirmed to be in the range of $180 to $160 million for fiscal year 2024.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time today, November 8, 2023, to discuss the financial results for Q2 FY2024 and report on business progress.

ProPhase Labs to Present at the Spring Into Action – Best Ideas Virtual Investor Conference

Retrieved on: 
Wednesday, May 11, 2022
Severe acute respiratory syndrome coronavirus 2, DNA, Company, Gene, Nasdaq, NASDAQ, OTC, Chromosome, Health Action International, COVID-19, Marketing, COVID-19 testing, Research, TK, Prophase, Dietary supplement, RT-PCR, Institution, PCR, Genomics, CLIA, Acquisition, Laboratory, GLOBE, Vaccine

Garden City, NY, May 11, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that Chairman and CEO Ted Karkus will present at the Spring Into Action Best Ideas Virtual Investor conference, which is being held virtually on May 17th-20th, 2022.

Key Points: 
  • Garden City, NY, May 11, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that Chairman and CEO Ted Karkus will present at the Spring Into Action Best Ideas Virtual Investor conference, which is being held virtually on May 17th-20th, 2022.
  • Mr. Karkus will be available for one-on-one meetings to be held throughout the conference.
  • To receive additional information, request an invitation or to schedule a one-on-one meeting, please email [email protected] .
  • ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.